- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03519373
Pertussis Immunization During Pregnancy & HIV Infection
Impact of HIV Infection and Pregnancy on Humoral Responses to Pertussis Immunization
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Despite the growing importance of maternal immunization in the control of infectious pathogens in early life, the impact of pregnancy on vaccine immunogenicity remains poorly understood. Evidence suggests that pregnancy may influence the quality of the antibody response to vaccines. Pregnancy is associated with modifications in the glycosylation profile of immunoglobulins G (IgG). Different patterns of glycosylation are associated with differential regulation of the effector functions of IgG such as antibody-dependent cell cytotoxicity, complement activation or antibody dependent phagocytosis. Whether similar modifications affect vaccine-induced IgG in pregnant women is unknown.
HIV infection is associated with important alterations in B cells and antibodies. Although antiretroviral therapy partly corrects the proportions of memory B cells (MBC) subsets, it does not restore B cell responses to vaccines, measured as seroconversion rates and antibody persistence. Reduced IgG responses to vaccines have been observed in HIV-infected pregnant women but the impact of HIV on the quality of vaccine-induced IgG has not been reported. On the other hand, HIV infection in pregnancy has a strong impact on the transfer of maternal IgG to the newborn, possibly as a consequence of hypergammaglobulinemia and immune activation.
The investigators will:
- Assess the respective impact of pregnancy and HIV infection on the magnitude and quality of B cell and antibody responses to pertussis immunization with the TDaP vaccine.
- Assess the impact of HIV infection and of the timing of maternal immunization on the transplacental transfer and on the quality of pertussis-specific IgG in the newborn.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, 1000
- CHU Saint-Pierre
-
Ixelles, Belgium, 1050
- HIS Etterbeek Ixelles
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age over 18
- HIV-infected or uninfected pregnant women in their second/third trimester with an indication of TDaP vaccination
- Non pregnant HIV negative women (having a negative HIV test in the last 6 months or at screening) with an indication of TDaP vaccination
Exclusion Criteria:
- Grade III/IV anemia
- Active bacterial infection
- Opportunistic infection (Tuberculosis, CMV, toxoplasmosis, etc)
- Inability to understand the nature and extent of the study and the procedures required
- Current or recent use of immunosuppressive drugs (corticosteroids, anti-TNF, methotrexate, etc)
- Active neoplasia
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
PER001
HIV 1-infected pregnant women
|
Tetanus, Diphteria and Acellular Pertussis vaccine (Boostrix)
|
|
PER002
HIV 1-uninfected pregnant women
|
Tetanus, Diphteria and Acellular Pertussis vaccine (Boostrix)
|
|
PER003
HIV 1-uninfected non-pregnant women
|
Tetanus, Diphteria and Acellular Pertussis vaccine (Boostrix)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pertussis-specific antibodies GMC after immunization
Time Frame: 7-10 days, 30 days and at delivery for pregnant women
|
Anti-Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and pertactin (PRN) specific antibodies levels
|
7-10 days, 30 days and at delivery for pregnant women
|
|
Transplacental transfer of pertussis-specific antibodies
Time Frame: Birth
|
Anti-PT, FHA and PRN specific antibodies levels transfer ratio
|
Birth
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pertussis-specific memory B cells quantification & phenotype
Time Frame: 7-10 days, 30 days and at delivery for pregnant women
|
PT, FHA and PRN-specific memory B cells numbers assessed by ELISPOT assay & Flow Cytometry
|
7-10 days, 30 days and at delivery for pregnant women
|
|
Pertussis-specific antibodies glycosylation profiles
Time Frame: 7-10 days, 30 days and at delivery for pregnant women
|
Anti-PT, FHA and PRN specific antibodies profiles
|
7-10 days, 30 days and at delivery for pregnant women
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nicolas Dauby, M.D. Ph.D., Centre Hospitalier Universitaire Saint Pierre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Urogenital Diseases
- Genital Diseases
- Pathologic Processes
- Disease Attributes
- Immune System Diseases
- Respiratory Tract Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Negative Bacterial Infections
- Bordetella Infections
- HIV Infections
- Infections
- Communicable Diseases
- Whooping Cough
Other Study ID Numbers
- Pertussis
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.